Video
Dr. Albala on the recent CMS change for Rezum water vapor therapy
Author(s):
“I think this really now suggests that Rezum is a financially viable procedure across these different treatment settings…the reimbursement now is really quite favorable,” says David M. Albala, MD.
Video Player is loading.
In this video, David M. Albala, MD, discusses the recent change made by the Centers for Medicare & Medicaid Services regarding Rezum water vapor therapy. This new change allows for more financial coverage for patients with benign prostatic hyperplasia (BPH) who seek this treatment. Albala is a urologist at Associate Medical Professionals and chief of urology at Crouse Hospital in Syracuse, New York.
Related Videos
BLUES trial: Silicone stents may improve patient care
Roshan Patel, MD, on the impact of restricted irrigation on PCNL outcomes
Jason Scovell, MD, on clinical utility of IsoPSA across racial groups
Jared S. Winoker, MD, discusses real-world study of CVAC 2.0 for kidney stones
Jim Hu, MD, on urinary continence recovery across RARP techniques
Dean Elterman, MD, shares 3-year data on Zenflow Spring System for BPH
Adoption of New Treatment Modalities to Treat BPH
Mohit Khera, MD, on the impact of penile prosthesis implant on mental health
Special Report: Tips for PCPs on evaluating prostate cancer risk
Maria Uloko, MD, discusses the lack of resident training on female sexual dysfunction
Related Content
